A-85 | Clinical Outcomes with DOACs versus Warfarin in Severely Obese (BMI ≥40 kg/m2) Patients with Atrial Fibrillation: A Real-World Propensity-Matched Study

Key Result

DOACs were compared to warfarin for clinical outcomes in severely obese patients with atrial fibrillation, but the provided abstract does not report the study results.

Key Points

• This study aims to compare the clinical outcomes of direct oral anticoagulants (DOACs) and warfarin in patients with severe obesity and atrial fibrillation.
• Real-world propensity-matched study design
• Focus on patients with a BMI ≥40 kg/m2 diagnosed with atrial fibrillation
• Comparison of outcomes between those treated with DOACs and those treated with warfarin.
• Limited data available on efficacy of DOACs in severely obese patients with atrial fibrillation, indicating potential disparities in treatment outcomes.
• Concerns regarding altered pharmacokinetics in this population suggest the need for cautious prescribing of anticoagulants.